Live Analyst Rating Changes 1525 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Craig Wong-Pan
RBC
Craig Wong-Pan
RBC Capital
Wall Street Analyst
Not yet ranked — too few measurable calls.
0%
Success Rate
-5.4%
Average Return
0 of 1 calls profitable · -9.3% vs benchmark
📈 Across the calls we could measure, roughly 0% of Craig Wong-Pan's ratings turned a profit when each position was held for 2 year — averaging -5.4% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

28 Buy 51 Hold 3 Sell
Craig's Stock Coverage 17 ratings · 2026-06-19
Company Date Position Consensus ⓘ Price Target ⓘ 2-Yr Return
AU:MVF
Monash IVF Group Ltd
 Jun 11, 2026 HOLD Strong Buy
+36.3% avg upside
7 analysts
$0.72
0.08% Upside
 ·
AU:IDX
Integral Diagnostics Ltd.
 May 28, 2026 BUY Strong Buy
+59.2% avg upside
12 analysts
$3.05
56.27% Upside
 ·
AU:REG
Regis Healthcare Ltd.
 May 25, 2026 BUY Strong Buy
+3.2% avg upside
6 analysts
$7.50
22.06% Upside
 ·
AU:ALC
Alcidion Group Limited
 May 18, 2026 HOLD Buy
+45.6% avg upside
2 analysts
$0.13
31.26% Upside
 ·
AU:HLS
Healius Limited
 May 13, 2026 SELL Sell
+109.7% avg upside
10 analysts
$0.35
14.67% Downside
 ·
AU:CSL
CSL
 May 11, 2026 HOLD Strong Buy
+63.9% avg upside
15 analysts
$113.00
1.56% Upside
 ·
RMD
Resmed
 May 01, 2026 BUY Buy
+25.4% avg upside
27 analysts
$321.00
70.18% Upside
 -5.4%
AU:COH
Cochlear
Apr 22, 2026 BUY Hold
+51.8% avg upside
15 analysts
$125.00
9.03% Upside
 ·
AU:TLX
Telix Pharmaceuticals
 Apr 15, 2026 BUY Strong Buy
+75.9% avg upside
13 analysts
$18.00
24.07% Upside
 ·
AU:RHC
Ramsay Health Care
 Feb 26, 2026 HOLD Hold
+1.7% avg upside
14 analysts
$45.00
14.73% Upside
 ·
AU:NAN
Nanosonics Limited
 Feb 24, 2026 HOLD Hold
+45.1% avg upside
7 analysts
$3.75
15.35% Upside
 ·
AU:SHL
Sonic Healthcare Limited
 Feb 19, 2026 HOLD Buy
+30.8% avg upside
12 analysts
$25.00
25.43% Upside
 ·
AU:ANN
Ansell
 Feb 16, 2026 BUY Buy
+12.4% avg upside
9 analysts
$41.00
36.62% Upside
 ·
AU:ACL
Australian Clinical Labs Ltd
 Feb 16, 2026 HOLD Hold
+30.4% avg upside
6 analysts
$2.40
9.91% Upside
 ·
AU:CAR
CAR Group
 Oct 06, 2020 SELL Buy
+9.7% avg upside
4 analysts
$16.04
42.11% Downside
 ·
AU:SEK
Seek Limited
 Oct 06, 2020 BUY Strong Buy
+81.7% avg upside
4 analysts
$31.60
135.74% Upside
 ·
AU:ALQ
ALS
 May 22, 2019 SELL Strong Sell
-71.5% avg upside
1 analyst
$6.57
71.51% Downside
 ·
🔒 12 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Craig Wong-Pan — Frequently Asked Questions
How accurate are Craig Wong-Pan's stock ratings?
Based on the calls 13Foresight could measure, about 0% of Craig's ratings were profitable over a one-year hold, with an average return of -5.4% per rating, or -9.3% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Craig ranked on 13Foresight?
Craig Wong-Pan is currently ranked unranked . Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Craig cover?
Craig most recently has ratings on AU:MVF, AU:IDX, AU:REG, AU:ALC, AU:HLS, AU:CSL, RMD, AU:COH, AU:TLX, AU:RHC, AU:NAN, AU:SHL and 5 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.